Evolus, Inc. (EOLS): Operating Cash Flow
-$42.27M
Year ended 2025-12-31
-$15.38M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$42.27M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$18.00M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$34.01M | n/m | 2026-03-03, From 2023-01-01 |
| 2022-12-31 | -$84.91M | n/m | 2025-03-04, From 2022-01-01 |
| 2021-12-31 | -$33.39M | n/m | 2023-03-08, From 2021-01-01 |
| 2020-12-31 | -$57.87M | n/m | 2022-03-03, From 2020-01-01 |
| 2019-12-31 | -$93.38M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$25.67M | n/m | 2020-02-25, From 2018-01-01 |
| 2017-12-31 | -$13.22M | n/a | 2019-03-20, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Evolus, Inc. (EOLS) | 2025-12-31 | -$42.27M | n/m |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $127.04M | +22.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $28.63M | n/m |
| CorMedix Inc. (CRMD) | 2025-12-31 | $175.05M | n/m |
| Harrow, Inc. (HROW) | 2025-12-31 | $43.86M | n/m |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $3.71M | n/m |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $49.36M | -49.1% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$273.80M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $13.90M | n/m |
Compare EOLS, IRWD, XERS, CRMD side by side · Screen every company in Pharmaceutical Preparations ↗